SCHEMBL4546285

SCHEMBL4546285

CC1O[C@H](OC(=N)C(Cl)(Cl)Cl)C(OC(=O)c2ccccc2)C(C)[C@@H]1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS9 O00182 1/20 0.36
LGALS1 P09382 1/20 0.36
LGALS3 P17931 1/20 0.36
LGALS7; LGALS7B P47929 1/20 0.36
BCHE P06276 1/20 0.34
PTGES2 Q9H7Z7 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
CHRNA7 P36544 2/20 0.33
PTPN1 P18031 1/20 0.33
ABCB1 P08183 1/20 0.33
SELP P16109 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 2/20 0.33
HTR3E A5X5Y0 1/20 0.32
HTR3B O95264 1/20 0.32
HTR3A P46098 1/20 0.32
HTR3D Q70Z44 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4546330 1.00 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BBCHE
SCHEMBL26453842 1.00 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BBCHE
SCHEMBL26453845 1.00 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BBCHE
SCHEMBL4546244 1.00 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BBCHE
SCHEMBL16642199 1.00 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BBCHE
SCHEMBL12793885 0.94 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BBCHE
SCHEMBL12793661 0.94 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BBCHE
SCHEMBL23016407 0.89 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2
SCHEMBL22697915 0.89 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2
SCHEMBL2151139 0.89 LGALS9 (0.36) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTGES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420790-B2 Efficient and scalable process for the manufacture of Fondaparinux sodium RELIABLE BIOPHARMACEUTICAL CORPORATION (US) 2013-04-16 US disclosed
US-20120116066-A1 EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM RELIABLE BIOPHARMACEUTICAL CORPORATION (US) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116066-A1 EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM F11, F10, F2 LGALS9 1981/4885LGALS1 2590/4885LGALS3 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.